Home / About CAR T

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response³

The autologous anti-CD19 CAR T-cell therapy,
TECARTUS^®, is individually prepared from each patient’s
T cells in a 6-step process¹:

The autologous anti-CD19 CAR T-cell
therapy, TECARTUS^®, is individually
prepared from each patient’s
T cells in a 6-step process¹:

Leukapheresis

Obtain peripheral blood mononuclear cells

Selection

Isolate T cells to reduce the
likelihood that circulating tumor
cells drive the exhaustion of
CAR T cells

Activation

Activate T cells using anti-CD3 and
anti-CD28 antibodies + IL-2

Transduction

Insert anti-CD19
CAR transgene

T-cell Expansion

In cell culture, expand the number of
CAR T cells to achieve dose

Suspension

Formulate CAR T cells into
suspension for infusion

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CD=cluster of differentiation; IL-2=interleukin-2.

References: 1. TECARTUS^® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file, Kite Pharma, Inc; 2023. 3. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9.

Up next: Design & Manufacturing >

SINGLE-INFUSION CAR T-CELL THERAPY WITH SURVIVAL EVALUATED AT 3 YEARS1,2

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response3

SINGLE-INFUSION CAR T-CELL THERAPY WITH SURVIVAL EVALUATED AT 3 YEARS^1,2

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response³